Proactive Investors
03 Jun 2026, 10:41 UTC · 2h ago
Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions
Proactive Investors
03 Jun 2026, 10:41 UTC · 2h ago
Story key points
5 claims · impact-rated
Deutsche Bank maintained a 'Sell' rating and a price target of 11,500p for AstraZeneca, which is significantly below the current share price of 13,064p. — A 'Sell' rating from a major institution with a price target ~12% below current levels suggests a bearish outlook on valuation.
-0.60The phase III EMERALD-3 trial showed a 30% reduction in the risk of disease progression or death for unresectable liver cancer patients using AstraZeneca's immunotherapy combination. — Positive phase III data for a major oncology drug is a fundamental driver of value and future revenue.
+0.40Deutsche Bank expressed uncertainty regarding whether the EMERALD-3 and SERENA-6 trials will secure regulatory approval. — Regulatory uncertainty for key pipeline drugs creates risk and can lead to negative price action if approvals are denied.
-0.30Continue reading
6 related stories
Search tags
Third-party prescriber polls show mixed results for the early commercial launch of the recently FDA-approved hypertension treatment Baxfendy. — Mixed early adoption signals potential commercial headwinds for a new product launch.
-0.20AstraZeneca expects phase III readouts for laroprovstat, balcinrenone, and zibotentan in 2027, with results for Wainua expected in 2026. — These represent future catalysts that could drive stock movement, though they are too distant for immediate impact.
+0.10Ticker attribution
Model heads
Deutsche Bank maintained a sell rating and noted unresolved regulatory questions and a lack of plenary presence at ASCO.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
2 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
Seeking Alpha
4h ago
